Drug Information

Drug General Information
Drug ID
D09DJC
Former ID
DNCL002746
Drug Name
IRX4204
Drug Type
Small molecular drug
Indication Prostate cancer [ICD9: 185; ICD10:C61] Phase 1 [525182]
Company
Io Therapeutics
Formula
C24H32O2
PubChem Compound ID
9863341
Target and Pathway
Target(s) Retinoic acid receptor RXR-gamma Target Info Modulator
KEGG Pathway PPAR signaling pathway
Thyroid hormone signaling pathway
Adipocytokine signaling pathway
Pathways in cancer
Transcriptional misregulation in cancer
Thyroid cancer
Small cell lung cancer
Non-small cell lung cancer
Pathway Interaction Database Regulation of Androgen receptor activity
RXR and RAR heterodimerization with other nuclear receptor
Retinoic acid receptors-mediated signaling
a6b1 and a6b4 Integrin signaling
Reactome Nuclear Receptor transcription pathway
WikiPathways Vitamin A and Carotenoid Metabolism
Adipogenesis
Nuclear Receptors
References
Ref 525182ClinicalTrials.gov (NCT02438215) Study of IRX4204 for Treatment of Early Parkinson's Disease. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.